14589 studies found for:    Canada
Show Display Options
Rank Status Study
1 Enrolling by invitation Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada
Condition: Chronic Hepatitis C
2 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
3 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
4 Enrolling by invitation Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis
Condition: Ulcerative Colitis
5 Recruiting Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Condition: Peripheral Artery Disease
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
6 Recruiting Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus
Interventions: Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
7 Recruiting Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention
Condition: Acute Coronary Syndromes
Interventions: Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
8 Recruiting Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
Condition: Crohn Disease
Intervention: Drug: etrolizumab
9 Recruiting Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients
Condition: Type 2 Diabetes Mellitus
Intervention: Drug: INSULIN GLARGINE (U300)
10 Recruiting Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older
Conditions: Atrial Fibrillation;   Hypertension
Intervention: Device: Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)
11 Recruiting Observational Study of Golimumab Intravenous Infusion
Condition: Rheumatoid Arthritis
Intervention: Biological: Golimumab Intravenous
12 Recruiting A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Condition: Prostatic Neoplasms
Intervention: Other: Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry
13 Recruiting Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
14 Recruiting Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
Condition: Major Depressive Disorder
Intervention: Drug: vortioxetine
15 Recruiting Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
Condition: Stroke
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
16 Recruiting Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: olodaterol;   Drug: tiotropium
17 Recruiting Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MEDI4736;   Drug: Placebo
18 Recruiting A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Condition: Psoriasis
Interventions: Drug: Guselkumab 100 mg;   Drug: Placebo for guselkumab;   Drug: Adalimumab;   Drug: Placebo for adalimumab
19 Recruiting Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
Condition: Psoriasis
Interventions: Drug: Adalimumab;   Drug: Methotrexate
20 Recruiting A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
Condition: Uncontrolled Asthma
Interventions: Biological: Experimental: Tralokinumab;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years